EP0315219A3 - Pharmazeutische Präparate - Google Patents

Pharmazeutische Präparate Download PDF

Info

Publication number
EP0315219A3
EP0315219A3 EP19880119742 EP88119742A EP0315219A3 EP 0315219 A3 EP0315219 A3 EP 0315219A3 EP 19880119742 EP19880119742 EP 19880119742 EP 88119742 A EP88119742 A EP 88119742A EP 0315219 A3 EP0315219 A3 EP 0315219A3
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
active agent
reservoir
pharmaceutical composition
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19880119742
Other languages
English (en)
French (fr)
Other versions
EP0315219B1 (de
EP0315219A2 (de
Inventor
Thomas Kissel
Henriette Schrank
Hans-Rainer Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
Sandoz AG
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, LTS Lohmann Therapie Systeme AG filed Critical Sandoz AG
Priority to EP88119742A priority Critical patent/EP0315219B1/de
Priority to AT88119742T priority patent/ATE84975T1/de
Publication of EP0315219A2 publication Critical patent/EP0315219A2/de
Publication of EP0315219A3 publication Critical patent/EP0315219A3/de
Application granted granted Critical
Publication of EP0315219B1 publication Critical patent/EP0315219B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
EP88119742A 1984-03-01 1985-02-22 Pharmazeutische Präparate Expired - Lifetime EP0315219B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP88119742A EP0315219B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Präparate
AT88119742T ATE84975T1 (de) 1984-03-01 1985-02-22 Pharmazeutische praeparate.

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH100884 1984-03-01
CH1008/84 1984-03-01
CH175384 1984-04-06
CH1753/84 1984-04-06
EP88119742A EP0315219B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Präparate

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP85810072.0 Division 1985-02-22
EP85810072A Division EP0155229B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Zusammensetzungen

Publications (3)

Publication Number Publication Date
EP0315219A2 EP0315219A2 (de) 1989-05-10
EP0315219A3 true EP0315219A3 (de) 1991-03-06
EP0315219B1 EP0315219B1 (de) 1993-01-27

Family

ID=25686369

Family Applications (3)

Application Number Title Priority Date Filing Date
EP88119742A Expired - Lifetime EP0315219B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Präparate
EP88119741A Expired - Lifetime EP0315218B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Präparate
EP85810072A Expired - Lifetime EP0155229B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Zusammensetzungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP88119741A Expired - Lifetime EP0315218B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Präparate
EP85810072A Expired - Lifetime EP0155229B1 (de) 1984-03-01 1985-02-22 Pharmazeutische Zusammensetzungen

Country Status (18)

Country Link
EP (3) EP0315219B1 (de)
JP (2) JPH0667835B2 (de)
KR (1) KR920010392B1 (de)
AT (3) ATE89750T1 (de)
AU (2) AU578275B2 (de)
CA (1) CA1257837A (de)
DE (4) DE3587698T2 (de)
DK (2) DK175774B1 (de)
GR (1) GR850507B (de)
HK (2) HK157896A (de)
HU (1) HU197847B (de)
IE (2) IE61754B1 (de)
IL (1) IL74446A (de)
MY (1) MY101919A (de)
NZ (1) NZ211248A (de)
PH (1) PH24392A (de)
PT (1) PT80033B (de)
WO (1) WO1985003878A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU578275B2 (en) * 1984-03-01 1988-10-20 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Pharmaceutical compositions
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
HU202753B (en) * 1986-06-21 1991-04-29 Sandoz Ag Process for producing retard pharmaceutical compositions containing cetotiphene
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
DE3901551A1 (de) * 1989-01-20 1990-07-26 Lohmann Therapie Syst Lts Superfizielles therapeutisches system mit einem gehalt an einem antineoplastischen wirkstoff, insbesondere 5-fluoruracil
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
DE4116912A1 (de) * 1991-05-18 1992-11-26 Schering Ag Mittel zur transdermalen applikation enthaltend ergolin-derivate
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US6165988A (en) * 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
JPH11511731A (ja) * 1995-02-10 1999-10-12 ノエ・クリスチアン 粒状薬剤
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE19950066A1 (de) * 1999-10-16 2001-04-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut
JP4575632B2 (ja) * 1999-12-14 2010-11-04 帝國製薬株式会社 片頭痛緩和用薬剤
DE10011447A1 (de) * 2000-03-10 2001-09-20 Roehm Gmbh Dispersion mit nichtionischem Emulgator
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
JP5758290B2 (ja) * 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
WO2017037812A1 (ja) * 2015-08-29 2017-03-09 株式会社メドレックス 酸捕捉剤を含有する貼付製剤
WO2018199018A1 (ja) * 2017-04-26 2018-11-01 ニプロ株式会社 経皮吸収型製剤およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2502951B1 (fr) * 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
CH653256A5 (en) * 1981-04-06 1985-12-31 Sandoz Ag Microemulsion for cutaneous use
ATE20311T1 (de) * 1981-07-08 1986-06-15 Key Pharma Polymerische diffusionsmatritze propranolol enthaltend.
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
JPS5925320A (ja) * 1982-08-02 1984-02-09 Watanabe Yakuhin Kogyo Kk 薬物投与用貼付剤
AU578275B2 (en) * 1984-03-01 1988-10-20 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents. *

Also Published As

Publication number Publication date
HU197847B (en) 1989-06-28
HK157896A (en) 1996-08-30
DK324687A (da) 1987-06-25
DK502985D0 (da) 1985-10-31
IE850493L (en) 1985-09-01
EP0315219B1 (de) 1993-01-27
DE3587698T2 (de) 1994-04-28
ATE98876T1 (de) 1994-01-15
IL74446A0 (en) 1985-05-31
PH24392A (en) 1990-06-13
ATE103819T1 (de) 1994-04-15
KR850700218A (ko) 1985-12-26
EP0155229A3 (en) 1985-12-11
IE61754B1 (en) 1994-11-30
AU607496B2 (en) 1991-03-07
CA1257837A (en) 1989-07-25
DK164257B (da) 1992-06-01
EP0315218B1 (de) 1993-12-22
PT80033A (en) 1985-03-01
HK220096A (en) 1997-01-03
GR850507B (de) 1985-06-28
NZ211248A (en) 1988-10-28
IE940083L (en) 1985-09-01
DE3587048D1 (de) 1993-03-11
DE3587794T2 (de) 1994-08-04
EP0155229A2 (de) 1985-09-18
DE3587698D1 (de) 1994-02-03
AU1662688A (en) 1988-10-20
DE3587794D1 (de) 1994-05-11
AU578275B2 (en) 1988-10-20
DK324687D0 (da) 1987-06-25
EP0315218A2 (de) 1989-05-10
WO1985003878A1 (en) 1985-09-12
EP0155229B1 (de) 1993-05-26
AU4065085A (en) 1985-09-24
IL74446A (en) 1990-11-29
DE3587358T2 (de) 1993-11-04
IE81316B1 (en) 2000-09-20
JPS61501324A (ja) 1986-07-03
DK502985A (da) 1985-10-31
EP0315218A3 (de) 1991-03-06
JP2540019B2 (ja) 1996-10-02
EP0315219A2 (de) 1989-05-10
ATE89750T1 (de) 1993-06-15
KR920010392B1 (ko) 1992-11-27
DE3587048T2 (de) 1993-06-03
PT80033B (pt) 1987-10-20
DK175774B1 (da) 2005-02-14
HUT41644A (en) 1987-05-28
JPH0667835B2 (ja) 1994-08-31
JPH0748253A (ja) 1995-02-21
MY101919A (en) 1992-02-15
DE3587358D1 (de) 1993-07-01
DK164257C (da) 1992-10-19

Similar Documents

Publication Publication Date Title
EP0315219A3 (de) Pharmazeutische Präparate
WO2000007979A3 (en) Compounds and compositions for delivering active agents
CA2338358A1 (en) Compounds and compositions for delivering active agents
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2010218A1 (en) Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substances
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
EP0165696A3 (de) Transdermale Verabreichungsform
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
CA2004598A1 (en) Medicinal aerosol formulations
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
EP0315217A3 (de) Pharmazeutische Präparate
IE900245L (en) Transdermal drug delivery composition
IL89251A0 (en) Pharmaceutical compositions for the systemic transdermal administration of pharmacologically active agents
EP1676832A3 (de) Verbindungen und Zusammentsetzungen zur Freisetzung von Aktivstoffen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19881126

AC Divisional application: reference to earlier application

Ref document number: 155229

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19911108

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 155229

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 84975

Country of ref document: AT

Date of ref document: 19930215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3587048

Country of ref document: DE

Date of ref document: 19930311

ITF It: translation for a ep patent filed

Owner name: SANDOZ PRODOTTI FARMACEUTICI S.P.A.

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 88119742.0

ITTA It: last paid annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: SANDOZ AG;LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG TRANSFER- LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG;NOVARTIS AG

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

NLS Nl: assignments of ep-patents

Owner name: LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG;NOVARTI

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040112

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20040113

Year of fee payment: 20

Ref country code: AT

Payment date: 20040113

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20040120

Year of fee payment: 20

Ref country code: DE

Payment date: 20040120

Year of fee payment: 20

Ref country code: CH

Payment date: 20040120

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20040122

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040126

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040128

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20050221

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20050221

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20050221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20050222

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20050222

BE20 Be: patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050222

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20050222

BE20 Be: patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050222